Home LiteratureArticle Details
PMID: 6414692 Published · ppublish English Clinical Trial Journal Article

Clinical overview of mesna.

Cancer treatment reviews ·Vol. 10 Suppl A ·1983-09-00 ·Pages 175-81

Burkert H

Abstract

Mesna is superior to standard prophylaxis in inhibiting the urotoxicity of oxazaphosphorines. Mesna does not interfere with the antitumour effect of oxazaphosphorines and other cytostatics. Mesna is well tolerated. Mesna can be given orally. Mesna should be administered with each ifosfamide treatment and with high dose cyclophosphamide. It should also be given to any patient who may be at risk of developing cystitis following oxazaphosphorine treatment.

MeSH Terms
Clinical Trials as Topic Cyclophosphamide/adverse effects Drug Interactions Hematuria/chemically induced,prevention & control Humans Ifosfamide/adverse effects Mercaptoethanol/analogs & derivatives Mesna/administration & dosage,therapeutic use Neoplasms/drug therapy
Chemicals
Mercaptoethanol Cyclophosphamide Mesna Ifosfamide
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Burkert H
Article Info
Journal
Cancer treatment reviews
Abbr.
Cancer Treat Rev
ISSN
0305-7372
Published
1983-09-00
Pages
175-81
Language
English
Region
Netherlands
NLM ID
7502030
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]